Literature DB >> 11499871

A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro.

T Yoneda1, P J Williams, T Hiraga, M Niewolna, R Nishimura.   

Abstract

Breast cancer has a predilection for spreading to bone. The mechanism of preferential metastasis of breast cancer to bone is unknown. We hypothesize that breast cancer cells that develop bone metastases have the capacity to facilitate their colonization in bone. To examine this hypothesis, we established bone-seeking (MDA-231BO) and brain-seeking (MDA-231BR) clones of the human breast cancer cell line MDA-MB-231 by repeated sequential passages in nude mice and in vitro of metastatic cells obtained from bone and brain metastases, respectively. These clones were examined for distinguishing biological characteristics and compared with the MDA-231 parental cells (MDA-231P) in vivo and in vitro. Both the MDA-231BR and the MDA-231BO showed identical tumorigenicity to MDA-231P at the orthotopic site. MDA-231P that was inoculated into the heart developed metastases in bone, brain, ovary, and adrenal glands. On the other hand, MDA-231BO exclusively metastasized to bone with larger osteolytic lesions than MDA-231P. MDA-231BR exclusively disseminated to brain and failed to develop bone metastases. In culture, MDA-231BO produced greater amounts of parathyroid hormone-related protein (PTH-rP) than MDA-231BR and MDA-231P in the absence or presence of transforming growth factor beta (TGF-beta). Furthermore, the anchorage-independent growth of MDA- 231BO in soft agar was not inhibited by TGF-beta, whereas TGF-beta profoundly inhibited the growth of MDA-231P and MDA-231BR. Insulin-like growth factor I (IGF-I) markedly promoted the anchorage-independent growth of MDA-231BO, whereas marginal or no stimulation was observed in MDA-231BR or MDA-231P, respectively. Our data suggest that these phenotypic changes allow breast cancer cells to promote osteoclastic bone resorption, survive, and proliferate in bone, which consequently leads to the establishment of bone metastases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11499871     DOI: 10.1359/jbmr.2001.16.8.1486

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  214 in total

1.  Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI.

Authors:  Matthew D Budde; Eric Gold; E Kay Jordan; Joseph A Frank
Journal:  Clin Exp Metastasis       Date:  2011-11-01       Impact factor: 5.150

2.  Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases.

Authors:  Toru Hiraga; Akira Myoui; Nobuyuki Hashimoto; Akira Sasaki; Kenji Hata; Yoshihiro Morita; Hideki Yoshikawa; Clifford J Rosen; Gregory R Mundy; Toshiyuki Yoneda
Journal:  Cancer Res       Date:  2012-06-27       Impact factor: 12.701

3.  Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain.

Authors:  Yongzhen Qian; Emily Hua; Kheem Bisht; Stephan Woditschka; Konstantine W Skordos; David J Liewehr; Seth M Steinberg; Edi Brogi; Muzaffar M Akram; J Keith Killian; Daniel C Edelman; Marbin Pineda; Stephanie Scurci; Yan Y Degenhardt; Sylvie Laquerre; Thomas A Lampkin; Paul S Meltzer; Kevin Camphausen; Patricia S Steeg; Diane Palmieri
Journal:  Clin Exp Metastasis       Date:  2011-09-21       Impact factor: 5.150

4.  Cellular fibronectin 1 promotes VEGF-C expression, lymphangiogenesis and lymph node metastasis associated with human oral squamous cell carcinoma.

Authors:  Yoshihiro Morita; Kenji Hata; Masako Nakanishi; Tetsuji Omata; Nobuo Morita; Yoshiaki Yura; Riko Nishimura; Toshiyuki Yoneda
Journal:  Clin Exp Metastasis       Date:  2015-08-29       Impact factor: 5.150

5.  Analysis of radiation therapy in a model of triple-negative breast cancer brain metastasis.

Authors:  DeeDee Smart; Alejandra Garcia-Glaessner; Diane Palmieri; Sarah J Wong-Goodrich; Tamalee Kramp; Brunilde Gril; Sudhanshu Shukla; Tiffany Lyle; Emily Hua; Heather A Cameron; Kevin Camphausen; Patricia S Steeg
Journal:  Clin Exp Metastasis       Date:  2015-08-30       Impact factor: 5.150

6.  Suppressive Effects of Plumbagin on Invasion and Migration of Breast Cancer Cells via the Inhibition of STAT3 Signaling and Down-regulation of Inflammatory Cytokine Expressions.

Authors:  Wei Yan; Bing Tu; Yun-Yun Liu; Ting-Yu Wang; Han Qiao; Zan-Jing Zhai; Hao-Wei Li; Ting-Ting Tang
Journal:  Bone Res       Date:  2013-12-31       Impact factor: 13.567

Review 7.  In vivo animal models for studying brain metastasis: value and limitations.

Authors:  Inderjit Daphu; Terje Sundstrøm; Sindre Horn; Peter C Huszthy; Simone P Niclou; Per Ø Sakariassen; Heike Immervoll; Hrvoje Miletic; Rolf Bjerkvig; Frits Thorsen
Journal:  Clin Exp Metastasis       Date:  2013-01-16       Impact factor: 5.150

8.  Novel modeling of cancer cell signaling pathways enables systematic drug repositioning for distinct breast cancer metastases.

Authors:  Hong Zhao; Guangxu Jin; Kemi Cui; Ding Ren; Timothy Liu; Peikai Chen; Solomon Wong; Fuhai Li; Yubo Fan; Angel Rodriguez; Jenny Chang; Stephen T C Wong
Journal:  Cancer Res       Date:  2013-10-04       Impact factor: 12.701

9.  Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2.

Authors:  Yasir H Ibrahim; Sara A Byron; Xiaojiang Cui; Adrian V Lee; Douglas Yee
Journal:  Mol Cancer Res       Date:  2008-09       Impact factor: 5.852

10.  Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.

Authors:  Brunilde Gril; Diane Palmieri; Julie L Bronder; Jeanne M Herring; Eleazar Vega-Valle; Lionel Feigenbaum; David J Liewehr; Seth M Steinberg; Maria J Merino; Stephen D Rubin; Patricia S Steeg
Journal:  J Natl Cancer Inst       Date:  2008-07-29       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.